# A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

> **NCT05785624** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 286 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis With Lung Involvement

## Interventions

- **DRUG:** Vixarelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05785624
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-26
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-01-12
- **Target enrollment:** 286 (ACTUAL)
- **Why stopped:** Sponsor decided to discontinue the study after review of clinical data by the iDMC. This decision was based on unblinded evaluation of clinical efficacy which showed a trend towards futility \& was not related to any safety concerns of vixarelimab.
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785624, "A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05785624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*